Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-473-7700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.07 million
Profitability
Miscellaneous
Employees18
Next Earnings Date3/15/2019 (Estimated)
OptionableOptionable
Geron (NASDAQ:GERN) Frequently Asked Questions
What is Geron's stock symbol?
Geron trades on the NASDAQ under the ticker symbol "GERN."
How were Geron's earnings last quarter?
Geron Co. (NASDAQ:GERN) announced its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.02. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.22 million. Geron had a negative net margin of 3,077.78% and a negative return on equity of 19.16%. View Geron's Earnings History.
When is Geron's next earnings date?
What price target have analysts set for GERN?
5 analysts have issued 1-year target prices for Geron's shares. Their forecasts range from $1.80 to $7.00. On average, they anticipate Geron's share price to reach $4.01 in the next twelve months. This suggests a possible upside of 178.8% from the stock's current price. View Analyst Price Targets for Geron.
What is the consensus analysts' recommendation for Geron?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.
Has Geron been receiving favorable news coverage?
Press coverage about GERN stock has been trending somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Geron earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the next several days.
Are investors shorting Geron?
Geron saw a increase in short interest in January. As of January 31st, there was short interest totalling 35,227,714 shares, an increase of 2.3% from the January 15th total of 36,046,089 shares. Based on an average daily trading volume, of 2,101,947 shares, the days-to-cover ratio is presently 16.8 days. Approximately 19.0% of the shares of the company are sold short. View Geron's Current Options Chain.
Who are some of Geron's key competitors?
Some companies that are related to Geron include Deciphera Pharmaceuticals (DCPH), Vanda Pharmaceuticals (VNDA), Rhythm Pharmaceuticals (RYTM), Puma Biotechnology (PBYI), CannTrust (CNTTF), Alder Biopharmaceuticals (ALDR), Epizyme (EPZM), Tricida (TCDA), Kiniksa Pharmaceuticals (KNSA), MacroGenics (MGNX), Homology Medicines (FIXX), Advanz Pharma (CXRXF), Retrophin (RTRX), Radius Health (RDUS) and Athenex (ATNX).
What other stocks do shareholders of Geron own?
Who are Geron's key executives?
Geron's management team includes the folowing people:
- Dr. John A. Scarlett, CEO, Pres & Chairman (Age 68)
- Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 50)
- Dr. Andrew J. Grethlein, Exec. VP & COO (Age 55)
- Mr. Stephen N. Rosenfield, Exec. VP & Chief Legal Officer (Age 69)
- Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 55)
Who are Geron's major shareholders?
Geron's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.07%), Northern Trust Corp (1.16%), Geode Capital Management LLC (1.02%), Two Sigma Investments LP (0.53%), Millennium Management LLC (0.40%) and Bank of New York Mellon Corp (0.38%). Company insiders that own Geron stock include Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.
Which major investors are selling Geron stock?
GERN stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, New York State Common Retirement Fund, Bank of New York Mellon Corp, Jane Street Group LLC and Raymond James Financial Services Advisors Inc.. Company insiders that have sold Geron company stock in the last year include Robert J Spiegel and Stephen Rosenfield. View Insider Buying and Selling for Geron.
Which major investors are buying Geron stock?
GERN stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Two Sigma Investments LP, D. E. Shaw & Co. Inc., Ibex Investors LLC, Virtu Financial LLC, Northern Trust Corp and Virtus ETF Advisers LLC. View Insider Buying and Selling for Geron.
How do I buy shares of Geron?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Geron's stock price today?
One share of GERN stock can currently be purchased for approximately $1.4385.
How big of a company is Geron?
Geron has a market capitalization of $268.06 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.
What is Geron's official website?
How can I contact Geron?
Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]
MarketBeat Community Rating for Geron (NASDAQ GERN)
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
